Bausch & Lomb Corp (BLCO) Stock
7 of the hedge funds AlphaScala tracks reported BLCO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Icahn Capital's at $57.96M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own BLCO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Icahn Capital Carl Icahn | 3.50M | $57.96M | n/a |
| D.E. Shaw David Shaw | 3.32M | $55.03M | +5% |
| Citadel Ken Griffin | 988K | $16.36M | +40% |
| Millennium Management Israel Englander | 177K | $2.93M | -42% |
| Point72 Steve Cohen | 176K | $2.91M | -38% |
| Third Point Dan Loeb | 85K | $1.41M | NEW |
| Marshall Wace | 70K | $1.16M | +10% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Bausch & Lomb Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 10, 26 | Munsch Frederick | SVP, Controller and CAO | SELL | 52.9K | $888K |
| Aug 7, 26 | Von Eschenbach Andrew C. | Director | SELL | 6.1K | $100K |
| Aug 6, 26 | Von Eschenbach Andrew C. | Director | SELL | 12.5K | $206K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →BLCO price chart
Powered by TradingViewWhat does Bausch & Lomb Corp do?
Bausch + Lomb Corporation, a leading health care company, primarily focuses on eye health products. The corporation specializes in the development, manufacture, and marketing of a comprehensive range of contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices, all designed to improve sight and enhance related health outcomes. Bausch + Lomb plays a crucial role in the vision care industry, impacting both everyday consumers and medical professionals by providing innovative solutions for vision correction and eye health. The company's offerings cater to diverse markets, including prescription eyewear, over-the-counter eye drops, and refractive laser systems used in medical facilities. Headquartered in Rochester, New York, Bausch + Lomb's commitment to advancing eye health is evident through its extensive research and development initiatives, which continually push the boundaries of eye care technology and treatment options. Through a strategic global presence, Bausch + Lomb significantly contributes to the eye health sector, addressing the growing demand for reliable and advanced vision care products worldwide.